NFE2L2 and autoimmune disease: (iv) The majority of the patents related to Nrf2 and autoimmune diseases from 2017–2020 focus on the use of nonelectrophilic Nrf2 pathway activators, which are shown or postulated to directly inhibit the Keap1–Nrf2 protein–protein interaction.